News | May 11, 2023
FSD Pharma completes dosing of first cohort in Phase I clinical trial of Lucid-MS
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression
Clinical data to date shows efti uniquely positioned to address entire NSCLC patient population through both chemo-free IO-IO and IO-IO-chemo triple combinations
The order marks a significant milestone for MMP Industries that will contribute to the company's revenue in the coming financial year
Spain’s renowned centre of excellence recognises importance of verifying radiosurgery plans ahead of patient treatment
The facility has been set up to manufacture tuberculosis testing cartridges
The WHO - Global Center for Traditional Medicine will help member countries in taking enabling steps in their countries for strengthen education and practices of traditional mdicine
Sonowal exhorted young researchers and scientist to work on evidence based scientific research
Ayurveda is one of the most advanced sciences of its times
BDRs journey for the treatment of Prostate Cancer started with Abiratarone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.
Subscribe To Our Newsletter & Stay Updated
